Nadofaragene firadenovec-vncg (Adstiladrin) Coverage Policy
Customize your policy alerts
Sign up for Ambetter Nevada Policy CP.PHAR.461 alerts
Get alerted when Policy CP.PHAR.461 changes without checking for updates manually.
Monitor payer policy activity
Prior authorization and medical-necessity coverage for Adstiladrin in adults with high-risk, BCG-unresponsive non-muscle-invasive bladder cancer across commercial, HIM/ICHRA, and Medicaid lines of business.
HCPCS code J9029 was added for intravesical instillation of nadofaragene firadenovec-vncg per therapeutic dose.
The initial approval criteria requirement for clinically significant elevated liver or renal function tests was removed.
The policy was updated after Adstiladrin received FDA approval without significant changes to the approval criteria.
The policy removed the initial-therapy requirement for clinically significant elevated liver or renal function tests.
The policy added oncology dosing criteria permitting doses supported by practice guidelines or literature.
The policy added an off-label indication for Ta/T1 high-grade disease without carcinoma in situ and added a requirement that the member not be a candidate for cystectomy.
The policy removed the lifetime dose requirement, clarified that treatment frequency must not exceed every three months, and removed the specification that treatment consist of a single dose.
The policy increased the initial and continued therapy approval duration to 12 months for this maintenance medication.
HCPCS code J9029 was added as the referenced billing code for nadofaragene firadenovec-vncg intravesical instillation.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.